摘要
银屑病是一种免疫紊乱介导的以皮肤慢性炎症性改变为主的系统性疾病,临床表现为皮肤红斑鳞屑,可累及指(趾)甲及关节。IL-12和IL-23是参与银屑病发病的重要细胞因子,乌司奴单抗是靶向抑制IL-12和IL-23共有亚基p40的全人源单克隆抗体制剂,多项国内外随机对照临床试验结果表明,乌司奴单抗应用于中重度斑块型银屑病和关节病型银屑病的治疗可显著改善病情,提高患者生活质量,具有良好的有效性、长期稳定性和安全性。
Psoriasis is a systemic disease mediated by immune disorders that charaterized with chronic skin inflammatory.The clinical manifestations are erythema and scales,which may also involve fingernal,toenails and joints.Interleukin-12 and interleukin-23 are critical cytokines involved in the pathogenesis of psoriasis.Ustekinumab is a humanized biological agent targeting the common subunit p40 of interleukin-12 and interleukin-23.Several randomized controlled clinical trials showed that ustekinumab can significantly improve the skin lesions and enhance the quality of life of patients with moderate to severe plaque psoriasis,psoriatic nail damage and arthritis psoriasis.It exhibits effective,long-term stability and safety in the treatment psoriasis.
作者
张洋洋
王刚
ZHANG Yangyang;WANG Gang(Department of Dermatology,Xijing Hospital,Fourth Military Medical University,Xi'an 710032,China)
出处
《中国皮肤性病学杂志》
CAS
CSCD
北大核心
2020年第4期454-457,共4页
The Chinese Journal of Dermatovenereology
